Don't let soupy spuds and gray beans bring you down - there's a canned veggie out there that's even more nutritious than its ...

Eli Lilly and Novo Nordisk are the main players in the GLP-1 field, but they're facing competition from compounding pharmacies, telehealth companies and even themselves. Since Eli Lilly's Mounjaro and ...

However, one of the major gripes about semaglutide (the active ingredient in Novo Nordisk's Ozempic and Wegovy) and ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Wednesday’s update to the regulator’s drug shortage database is good news for Novo Nordisk, which has struggled to keep up ...

Intense competition from Viking Therapeutics and ... landscape threaten Novo's performance moving forward. Because Ozempic was first marketed for the treatment of diabetes, these supposed 'junk ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Factory closures in France are expected to affect "thousands of jobs" in the coming weeks and months, Industry Minister Marc ...

Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 full-year ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

The seemingly inexorable rise in global obesity is being reflected in the sales of diabetes and weight-loss drugs, including ...

Advertisement The commission found Teva either tried to slow down competitors or block them ... with nutritional counseling Sanders tells Ozempic drugmaker's CEO to stop 'ripping off' Americans ...